<DOC>
	<DOCNO>NCT02696070</DOCNO>
	<brief_summary>This study design evaluate effectiveness Provant Therapy System improve localized nerve growth skin perfusion subject painful peripheral diabetic neuropathy foot .</brief_summary>
	<brief_title>Nociceptive Pain Fiber Response</brief_title>
	<detailed_description>The study multi-site , randomize , double-blind , sham-controlled study safety efficacy multi-dose Provant therapy evaluate neuronal vascular response treatment subject painful peripheral diabetic neuropathy . Subjects randomize 2:1 ratio receive therapy active device identical inactive sham device . Subjects treat home twice daily 60 day return clinic final evaluation . Subjects evaluate research center Baseline/Enrollment visit Day 61 assessment safety , concomitant medication , Sympathetic Skin Response ( SSR ) , Nerve Conduction Velocity ( NCV ) , Skin Perfusion Pressures ( SPP ) , Skin Biopsy complete . Subjects contact via telephone Day 14 , Day 28 Day 42 ass adherence , safety , concomitant medication . Subjects also complete Response Study Device form capture daily pain score .</detailed_description>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . Subject age great equal 22 year less 80 year age . 2 . Subject document Type 2 diabetes . 3 . Subject HgbA1c &gt; 7 % &lt; 10 % . 4 . Subject peripheral diabetic neuropathy pain , numbness , tingle , and/or burn least one foot confirm positive provocative sign positive Tinel 's sign . If foot involve , one great severity select index foot . 5 . Subject pain Phase 2 , 3 , 4 ( Appendix C ) . 6 . Subject willing able give write informed consent comply part study protocol include diary entry . 7 . Female subject must postmenopausal , surgically sterile , abstinent , practicing ( agree practice ) effective method birth control sexually active duration study . ( Effective method birth control include prescription hormonal contraceptive , intrauterine device , doublebarrier method , and/or male partner sterilization ) . 1 . Subject Type 1 diabetes . 2 . Subject pain Phase 1 5 ( Appendix C ) . 3 . Subject active , open ulcer either low extremity arterial , venous mixed disease origin . 4 . Subject peripheral arterial disease determine AnkleBrachial Index ( ABI ) &gt; 1.40 &lt; 0.80 . See Appendix E detail obtain ABI . NOTE : If difference brachial pulse pressure right leave arm &gt; 10 mmHg , subject eligible enrollment refer cardiologist evaluation . 5 . Subject venous insufficiency classify Venous Insufficiency Classification System ( CEAP ) grade C3 , C4 , C5 , C6 . See Appendix F description venous insufficiency grade . 6 . Subject undergone decompression surgery index foot treat peripheral neuropathy within 2 year Screening Visit . 7 . Subject require anticipates need surgery type 60 day treatment period . 8 . Subject smoker smoker within one year Screening Visit . 9 . Subject total foot thickness ( plantar surface middorsal surface ) &gt; 6 centimeter . 10 . Subject anticipate travel course 60 day treatment period . 11 . Subject receive investigational drug device within 30 day 5 halflives drug , whichever longer , prior Screening Visit enrol another clinical trial . 12 . Subject undergone local injection index foot within 30 day prior Screening Visit within 6 week prior Screening Visit long act lidocaine injection product . 13 . Subject use systemic corticosteroid within 2 month Screening Visit . 14 . Subject history uncontrolled medical illness investigator 's judgment place subject unacceptable risk receipt PEMF therapy . 15 . Subject history malignancy within past five year successfully treat nonmetastatic basal cell squamous cell carcinoma skin treatment area and/or localize situ carcinoma cervix . 16 . Subject serious psychosocial comorbidity . 17 . Subject history drug alcohol abuse , confirm urine drug screen , within one year prior Screening Visit . 18 . Subject implanted pacemaker , defibrillator , neurostimulator , spinal cord stimulator , bone stimulator , cochlear implant , implanted device implant metal lead ( ) . 19 . Subject currently pregnant plan become pregnant prior Day 60 . 20 . Subject previously treat PROVANT Therapy System . 21 . Subject unwilling unable follow study instruction , comply treatment regimen study visit .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Diabetic Neuropathy</keyword>
	<keyword>Pulsed Electromagnetic Energy Field</keyword>
	<keyword>PEMF</keyword>
	<keyword>PPDN</keyword>
</DOC>